Navigation Links
FDA Approves MIRCERA(R): First Renal Anemia Treatment with Monthly Maintenance Dosing
Date:11/14/2007

NUTLEY, N.J., Nov. 14 /PRNewswire-USNewswire/ -- Roche announced today that the U.S. Food and Drug Administration (FDA) has approved MIRCERA (methoxy polyethylene glycol-epoetin beta) for the treatment of anemia associated with chronic renal failure (CRF) in adults, including patients on dialysis and patients not on dialysis. CRF is commonly known as chronic kidney disease (CKD). MIRCERA is the only FDA-approved erythropoiesis-stimulating agent (ESA) to provide correction of anemia with once-every-two-week dosing. MIRCERA is also the only FDA-approved ESA to maintain stable hemoglobin levels with once-monthly or once-every-two-week dosing in CKD patients. MIRCERA offers the added convenience of storage at room temperature for extended time periods when necessary.

The outcome of an ongoing patent case will determine when patients can gain access to MIRCERA in the United States. Following approval by the European Agency for the Evaluation of Medicinal Products (EMEA), MIRCERA has already been launched in Austria, Sweden, Germany, the United Kingdom and Norway, and will continue its international rollout.

"Roche is pleased that the approved FDA label reflects the differentiating characteristics of MIRCERA," said George B. Abercrombie, President and Chief Executive Officer, Hoffmann-La Roche Inc. "In Europe, thousands of patients with chronic renal failure and their physicians are receiving effective, predictable and convenient anemia treatment with MIRCERA, and we are hopeful that patients and healthcare providers in the U.S. will be able to have access to MIRCERA as soon as possible, in a responsible and legal manner."

In contrast to erythropoietin, MIRCERA is an erythropoietin receptor activator with greater activity in vivo as well as increased half-life. MIRCERA has the longest half-life of all FDA-approved ESAs, up to six times longer than darbepoetin alfa and up to 20 times longer than epoetin.

The initial registration clinical
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 Parker Waichman LLP, a ... injured by defective medical devices, is offering remarks on the ... the Estate of Fred E. Taylor v. Intuitive Surgical, 09-2-03136-5, ... May 21, 2013, Bloomberg report noted that the ... a “car dealership” in how it deployed its strategy to ...
(Date:5/21/2013)... 2013 Parker Waichman LLP, a national ... injured by defective medical devices, is addressing new research ... on May 15, 2013. The study found that magnetic ... that occur in patients with metal-on-metal hip implants even ... ) , “We’ve known for quite ...
(Date:5/21/2013)... France: One-year results from SOURCE XT one of ... to-date reported today at EuroPCR 2013 show good ... of device success for all access approaches, valve sizes ... followed up 2688 consecutively enrolled patients (mean age 81.5 ... at 93 centres in 17 countries between July 2010 ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... Wright Conserve hip replacement lawsuits in ... an Order in response to a request from Plaintiffs’ ... of the Defendant. The May 17th Order grants ... interviews may be conducted. (In re: Wright Medical Technology, ...
(Date:5/21/2013)... Global Proving Ground (GPG), a fast rising ... retailer of health and fitness supplements, are partnering up ... Island. “We cast the show by having millions ... our unique social networking platform,” states show’s creator James ... an island in the Pacific Ocean, where they must ...
Breaking Medicine News(10 mins):Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 2Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 3Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3
... disparities in cost-effectiveness analysis, would allow policy makers ... reduce disparities between racial ethnic subgroups, and be ... in the Journal of the National ... be used to identify effective and cost-effective strategies ...
... , TUESDAY, Sept. 6 (HealthDay News) -- Breast ... much better response to neoadjuvant chemotherapy -- chemo given ... patients, a new study finds. U.S. researchers looked ... who underwent neoadjuvant chemotherapy. Complete pathological response (pCR) ...
... HealthDay Reporter , TUESDAY, Sept. 6 (HealthDay News) -- ... ibuprofen during the first stage of their pregnancy may ... "We,re seeing a 2.4-fold increased risk in ... said Anick Berard, senior author of a paper published ...
... An innovative approach to treating neonatal feeding problems at ... to feed orally to be discharged earlier and without ... According to American Academy of Pediatrics guidelines, ... the hospital, they must establish safe oral feeding methods. ...
... in German . The stomach bacterium Helicobacter ... development of gastric cancer, the third most common cause of cancer-related ... have now identified a mechanism of Helicobacter pylori that damages the ... for malignant transformation. Gastric cancer is one of the most ...
... been prescribing codeine for postpartum pain management for many years, ... taking the opioid. But the death of an infant ... providers questioning the safety of the drug when used by ... have begun the practice of prescribing oxycodone as an alternative ...
Cached Medicine News:Health News:Modeling disparities may help with cervical cancer prevention 2Health News:Going Straight to Chemo May Be Better for Certain Breast Cancers 2Health News:NSAIDs May Raise Miscarriage Risk: Study 2Health News:NSAIDs May Raise Miscarriage Risk: Study 3Health News:Neonatal and infant feeding disorders program saves infants from lifetime of feeding tubes 2Health News:Stomach bacterium damages human DNA 2Health News:Mother's postpartum oxycodone use: No safer for breastfed infants than codeine 2
(Date:5/21/2013)... Pa. , May 21, 2013  Lehigh Valley ... TRU-D SmartUVC TM devices, adding to its existing ... seven devices taking up residence within the network, LVHN ... the U.S. to proactively combat superbugs and provide the ... for Total Room Ultraviolet Disinfector, TRU-D – the signature ...
(Date:5/21/2013)... , May 21, 2013  Janssen R&D Ireland ... from the global Phase 3 PROMISE study demonstrating ... (TMC435) led to sustained virologic response 12 weeks ... percent of treatment-experienced genotype 1 chronic hepatitis C ... stages of liver fibrosis, when administered once daily ...
(Date:5/21/2013)... -- BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: ... cell based therapies for various personal applications, announced that ... CEO, will be presenting at the Marcum MicroCap Conference.   ... Thursday, May 30, 2013 at the Grand Hyatt Hotel, ... City.  Mr. Weinreb,s presentation will take place at 2:30 ...
Breaking Medicine Technology:Lehigh Valley Expands Fleet of Superbug-Slaying Robots 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
... , , SOUTHFIELD, Mich. ... ., (Nasdaq: TEAM ), a worldwide provider of information ... it has named Guido Roumans as director of global life ... management and ongoing capability enhancement in support of TechTeam,s life ...
... , MUMBAI, India , Feb. 9 ... a presence in India , Western and Central Eastern ... alliance with DreamCIS Inc., a leading CRO based in ... decade of experience in offering clinical research services to pharmaceutical ...
Cached Medicine Technology:TechTeam Global Appoints Life Sciences Services Director 2TechTeam Global Appoints Life Sciences Services Director 3SIRO Clinpharm Forms Alliance with Korean CRO DreamCIS 2SIRO Clinpharm Forms Alliance with Korean CRO DreamCIS 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: